Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. (Q47571494)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/25275236

Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. (English)

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/25275236

Jeff Richardson

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Silvio Garattini

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Michael Schlander

1

object named as

Michael Schlander

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Peter L Kolominsky-Rabas

4

object named as

Peter Kolominsky-Rabas

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

5

object named as

Erik Nord

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Oriol Sola-Morales

10

object named as

Oriol de Solà Morales

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

11

object named as

Keith Tolley

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

12

object named as

Mondher Toumi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Søren Holm

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ulf Persson

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Maarten Postma

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

1 July 2014

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/MED/25275236

Journal of Comparative Effectiveness Research

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

399-422

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25275236%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Adopting an orphan.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The future of orphan drug development

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Clinical pharmacology and orphan drugs: an informational inventory 2006-2010.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

National Institute for Clinical Excellence and its value judgments

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The price of innovation: new estimates of drug development costs

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The cost of drug development: a systematic review

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Drug development costs when financial risk is measured using the Fama-French three-factor model

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Global drug discovery: Europe is ahead.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Rare diseases, orphan drugs and their regulation: questions and misconceptions

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Economic evaluation of services for a National Health scheme: the case for a fairness-based framework

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Orphan drug development is progressing too slowly

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Orphan drug development is not taking off.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Translation of rare disease research into orphan drug development: disease matters

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Statistical challenges in the evaluation of treatments for small patient populations

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Critical ratios and efficient allocation

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The rationing debate: Maximising the health of the whole community. The case for.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Utility measurement in healthcare: the things I never got to.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Economics and ethics in health care

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The morality of efficiency in health care--some uncomfortable implications

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Willingness to pay for a QALY: theoretical and methodological issues

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Measures of efficiency in healthcare: QALMs about QALYs?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Vertical equity in health care resource allocation

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Legislating against use of cost-effectiveness information

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The policy analysis of 'values talk': lessons from Canadian health reform

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Can we estimate the 'social' value of a QALY? Four core issues to resolve.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Back to Bentham? Explorations of Experienced Utility

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Health economic guidelines--similarities, differences and some implications

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Need--is a consensus possible?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Cost-effectiveness league tables: valuable guidance for decision makers?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Cost utility analysis of sildenafil compared with papaverine-phentolamine injections

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Setting priorities in and for end-of-life care: challenges in the application of economic evaluation.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Palliative care for the terminally ill in America: the consideration of QALYs, costs, and ethical issues

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Development of a supportive care measure for economic evaluation of end-of-life care using qualitative methods

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Is economic evaluation in touch with society's health values?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

What values do the public want their health care systems to use in evaluating technologies?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Empiricism, ethics and orthodox economic theory: what is the appropriate basis for decision-making in the health sector?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

QALY maximisation and people's preferences: a methodological review of the literature.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Maximising health versus sharing: measuring preferences for the allocation of the health budget.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Severity of illness and priority setting in healthcare: a review of the literature.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Maximizing health benefits vs egalitarianism: an Australian survey of health issues.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Survival vs. quality of life: a study of the Israeli public priorities in medical care

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The rule of rescue

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

QALYfying the value of life

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The relevance of health state after treatment in prioritising between different patients

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Health state after treatment: a reason for discrimination?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

A qualitative study of the extent to which health gain matters when choosing between groups of patients

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Exploring the role of order effects in person trade-off elicitations.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Double jeopardy and the use of QALYs in health care allocation

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Double jeopardy and the veil of ignorance--a reply

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

QALYs, lotteries and veils: the story so far.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The moral relevance of personal characteristics in setting health care priorities

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Age-related preferences and age weighting health benefits.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The social value of health programmes: is age a relevant factor?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Age as a criterion for setting priorities in health care? A survey of the German public view

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

In defence of ageism

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Intergenerational equity: an exploration of the 'fair innings' argument

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Why the fair innings argument is not persuasive

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The 'fair innings argument' deserves a fairer hearing! Comments by Alan Williams on Nord and Johannesson.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Concerns for the worse off: fair innings versus severity

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Capabilities and health

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Examining preferences for allocating health care gains.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Assessing priorities for allocation of donor liver grafts: survey of public and clinicians

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Effect of discussion and deliberation on the public's views of priority setting in health care: focus group study

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Health care rationing: the public's debate

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Public preferences for the allocation of donor liver grafts for transplantation.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Distributing scarce livers: the moral reasoning of the general public.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

QALYs: the basics.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

A note on QALYs, time tradeoff, and discounting.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Information created to evade reality (ICER): things we should not look to for answers.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Orphan drugs and the NHS: should we value rarity?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Orphan drugs revisited.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The individual in mainstream health economics: a case of Persona Non-grata.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Who cares about cost? Does economic analysis impose or reflect social values?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

What is the price of life and why doesn't it increase at the rate of inflation?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Comparison of 5 health-related quality-of-life indexes using item response theory analysis

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Cost utility analysis: what should be measured?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Aversion to health inequalities and priority setting in health care.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Explicit incorporation of equity considerations into economic evaluation of public health interventions

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Can cost-effectiveness analysis integrate concerns for equity? Systematic review

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Wide Reflective Equilibrium and Theory Acceptance in Ethics

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Methods for quality adjustment of life years

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Identifying meaningful intra-individual change standards for health-related quality of life measures

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Methods to explain the clinical significance of health status measures

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Understanding the minimum clinically important difference: a review of concepts and methods.

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

A point of minimal important difference (MID): a critique of terminology and methods

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Coverage with evidence development: the Ontario experience

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Feasibility of randomised clinical trials in rare diseases: the case of polycythemia vera

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

A European perspective--the European clinical research infrastructures network

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Enhancing the rational use of new medicines across European health care systems

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Welfarism, extra-welfarism and capability: the spread of ideas in health economics

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Should the capability approach be applied in health economics?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Development of a self-report measure of capability wellbeing for adults: the ICECAP-A

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

An evaluation framework for funding drugs for rare diseases

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Is the valuation of a QALY gained independent of age? Some empirical evidence

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Rare diseases: what's next?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Cost-effectiveness league tables: More harm than good?

1 reference

https://api.crossref.org/works/10.2217%2FCER.14.34

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47571494&oldid=1858396515"